EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological Mechanisms of Action and Therapeutic Basis of Qihuang Jianpi Zishen Granules in Systemic Lupus Erythematosus: A Study Integrating Molecular Dynamics Simulation and Experimental Validation

Huining Li, Shuangping Li, Qingping Ye, Jingjing Li, Yumeng Li, Furui Chu, Sujun Xue, Chao Yu, Ni Wang, Chuanbing Huang, Xuerui Hu, Xianchun Duan

Chemistry & Biodiversity · 2026-11 · 23 (11)

DOI: 10.1002/cbdv.71896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 20.11.2026. Verfasst von Huining Li und 11 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to clarify the material basis and mechanism by which Qihuang Jianpi Zishen granules (QHJPZSG) treat systemic lupus erythematosus (SLE). UPLC‐Q‐TOF‐MS E was used to characterize the chemical constituents of QHJPZSG and its serum‐absorbed components in rats. Network pharmacology, molecular docking, and molecular dynamics simulations were applied to screen key active compounds, potential targets, and signaling pathways, followed by in vivo validation using MRL/lpr mice and in vitro verification with primary B cells. In total, 114 constituents were identified in QHJPZSG, including 27 prototype compounds and 51 metabolites in rat serum. A total of 141 overlapping drug‐disease targets were obtained; EGFR, ESR1, and MMP‐9 were identified as core targets with significantly enriched pathways. Molecular simulations revealed that biatractylolide, a major active ingredient of QHJPZSG, stably bound these core targets. In vivo, QHJPZSG relieved renal mesangial expansion and inflammatory infiltration in MRL/lpr mice. In vitro, QHJPZSG‐containing serum suppressed IL‐2, PKCα, ESR1, and MMP‐9 expression but increased EGFR levels. Collectively, QHJPZSG exerts anti‐SLE effects through a multi‐component, multi‐target mechanism, attenuating renal inflammation via the EGFR/ESR1/MMP‐9 pathway. This work provides experimental evidence supporting its clinical use.

Zitieren

APA

Li, H., Li, S., Ye, Q., Li, J., Li, Y., Chu, F., Xue, S., Yu, C., Wang, N., Huang, C., Hu, X., & Duan, X. (2026). Pharmacological Mechanisms of Action and Therapeutic Basis of Qihuang Jianpi Zishen Granules in Systemic Lupus Erythematosus: A Study Integrating Molecular Dynamics Simulation and Experimental Validation. Chemistry & Biodiversity, 23(11). https://doi.org/10.1002/cbdv.71896

Vancouver

Li H, Li S, Ye Q, Li J, Li Y, Chu F, et al. Pharmacological Mechanisms of Action and Therapeutic Basis of Qihuang Jianpi Zishen Granules in Systemic Lupus Erythematosus: A Study Integrating Molecular Dynamics Simulation and Experimental Validation. Chemistry & Biodiversity. 2026;23(11). doi:10.1002/cbdv.71896

BibTeX
@article{Li2026,
  author = {Li, Huining and Li, Shuangping and Ye, Qingping and Li, Jingjing and Li, Yumeng and Chu, Furui and Xue, Sujun and Yu, Chao and Wang, Ni and Huang, Chuanbing and Hu, Xuerui and Duan, Xianchun},
  title = {Pharmacological Mechanisms of Action and Therapeutic Basis of Qihuang Jianpi Zishen Granules in Systemic Lupus Erythematosus: A Study Integrating Molecular Dynamics Simulation and Experimental Validation},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  volume = {23},
  number = {11},
  doi = {10.1002/cbdv.71896}
}
Kostenlos starten →